11月25日晚间科森科技（603626）公告，因业务发展需要，公司拟在马来西亚投资新建生产基地，满足 境外客户的订单需求。 该公司消费电子产品包括智能手机、笔记本电脑、平板电脑、智能穿戴、智能音箱、加热不燃烧电子烟 结构件、VR等终端产品的外壳、中框、中板、按键、标志、转轴（铰链）组装等；医疗器械产品包括 手术刀、骨钉、心脏起搏器等终端产品所需结构件；储能产品主要为PACK模组产品等。 2025年前三季度，科森科技业绩延续亏损，期内实现营业收入24.53亿元，同比下滑6.45%；归母净利润 亏损1.15亿元，同比增长50.94%。 对于业绩亏损原因，该公司在2025年半年报中曾阐述，部分新产品处于量产爬坡阶段，产品毛利不及预 期；为突破技术瓶颈，争取更多的市场订单，公司研发费用保持较高投入。 该公司以全资子公司科森科技（新加坡）有限公司（下称"新加坡科森"）作为路径公司，在马来西亚柔 佛州设立森创力精密工业（马来西亚）私人有限公司（暂定名，最终以实际注册登记为准，下称"马来 西亚公司"）。公司本次拟投资金额为3000万美元，实际投资金额以中国及当地主管部门批准金额为 准。 据披露，马来西亚公司经营范围包括精密 ...

Core Insights - Highsight Medical (02407.HK) reported a revenue of 653 million yuan for the first half of 2025, reflecting a year-on-year growth of 1.7% [1] - The gross profit reached 316 million yuan with a gross margin of 48.3%, an increase of 1.8 percentage points [1] - Net profit surged to 35.9 million yuan, marking a year-on-year increase of 33.5% [1] Group 1: Financial Performance - The increase in gross margin and net profit is attributed to the rise in self-owned product revenue and continuous optimization of the revenue structure [1] - Self-owned business revenue reached 322 million yuan in the first half of 2025, contributing nearly half of the total revenue [2] - Self-owned product revenue was 203 million yuan, up 14.05% year-on-year, with artificial lenses contributing 171 million yuan, a growth of 11.4% [2] Group 2: R&D Investment and Product Development - R&D investment has consistently increased, from 41.09 million yuan in 2022 to 78.42 million yuan in 2024, with 43.4 million yuan spent in the first half of 2025, a 23.6% increase [1] - The proportion of R&D investment relative to self-owned product revenue rose from 13.3% in 2022 to 21.4% in the first half of 2025 [1] - The company has expanded its self-owned product portfolio to 72 items, with self-owned products contributing over 30% of total revenue [1] Group 3: Market Position and Strategy - The domestic market for ophthalmic medical devices, particularly surgical equipment, remains underdeveloped, presenting opportunities for growth [1] - Highsight Medical's dual strategy of "self-research products + high-end agency" supports its stable cash flow and competitive positioning [1] - The company has established a mature sales network covering 51 countries and regions, enhancing its market reach [1]